Intercell and Novartis collaborate on Pseudomonas vax

Intercell and Novartis are continuing to test an investigational vaccine for Pseudomonas aeruginosa. The disease can cause nosocomial infections that lead to pneumonia and other infections, usually during hospital stays, particularly in patients on ventilators. The 400-patient efficacy trial should start in the first half of 2012. Intercell release